ישראל - עברית - Ministry of Health

rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - טבליות בשחרור ממושך - oxycodone hydrochloride 10 mg; naloxone hydrochloride (as dihydrate) 5 mg - naloxone - naloxone - targin is indicated for the relief of moderate to severe pain.the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut

ישראל - עברית - Ministry of Health

rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - טבליות בשחרור ממושך - oxycodone hydrochloride 20 mg; naloxone hydrochloride (as dihydrate) 10 mg - naloxone - naloxone - targin is indicated for the relief of moderate to severe pain.the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut

ישראל - עברית - Ministry of Health

rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - טבליות בשחרור ממושך - oxycodone hydrochloride 5 mg; naloxone hydrochloride (as dihydrate) 2.5 mg - naloxone - naloxone - targin is indicated for the relief of moderate to severe pain.the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - טבליות בשחרור ממושך - naloxone hydrochloride (as dihydrate) 20 mg; oxycodone hydrochloride 40 mg - naloxone - naloxone - targin is indicated for the relief of moderate to severe pain.the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut

ישראל - עברית - Ministry of Health

rafa laboratories ltd - hydromorphone hydrochloride - תמיסה להזרקה - hydromorphone hydrochloride 20 mg / 2 ml - hydromorphone - hydromorphone - relief of moderate to severe pain such as that due to surgery or cancer.

ישראל - עברית - Ministry of Health

perrigo israel agencies ltd - benzoyl peroxide as hydrous 5 %w/w; clindamycin as phosphate 1 %w/w - gel - clindamycin - mild to moderate acne vulgaris, particulary inflammatory lesions.

ישראל - עברית - Ministry of Health

tzamal medical ltd - רופא - בהתאם להוראות היצרן

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 30000 iu / 0.75 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob